Anzeige
Mehr »
Lynx Broker
Login
Samstag, 19.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien
Magisch! Weg frei für die >Milliarden-Chance< im Pennystockmantel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 789617 ISIN: US09062X1037 Ticker-Symbol: IDP 
Tradegate
18.10.19
21:55 Uhr
197,90 Euro
-4,80
-2,37 %
1-Jahres-Chart
BIOGEN INC Chart 1 Jahr
5-Tage-Chart
BIOGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
196,90
198,08
18.10.
196,56
197,74
18.10.

Aktuelle News zur BIOGEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBiogen-Aktie ist unattraktiv!272Charlotte (www.aktiencheck.de) - Biogen-Aktienanalyse von Analyst Geoff Meacham von BofA Merrill Lynch Research: Im Rahmen einer Aktienanalyse rechnet Geoff Meacham, Aktienanalyst von BofA Merrill Lynch...
► Artikel lesen
DoSpinraza Worries Spark Bear Note for Biogen12
Börsennews zur BIOGEN Aktie und weiteren Hot Stocks erhalten
MiBiogen (BIIB) to Report Q3 Earnings: What's in the Cards?25
10.10.Better Buy: Biogen vs. Gilead Sciences48
09.10.Hedge Funds Have Never Been Less Bullish On Biogen Inc. (BIIB)20
09.10.The new top 20 pharma list: Takeda jumps on, Biogen pushed out - and more big changes are on the way18
09.10.Biogen Strengthens MS & SMA Portfolio as Competition Lurks6
03.10.Biogen Canada Reports Positive Results On Spinal Muscular Atrophy Study311WESTON (dpa-AFX) - Biogen Canada announced results from the NURTURE study, demonstrating that infants who initiated treatment with SPINRAZA or nusinersen injection prior to the onset of clinical...
► Artikel lesen
02.10.Biogen Inc.: Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA (nusinersen) Published in Neuromuscular Disorders348Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support...
► Artikel lesen
02.10.Biogen's R&D chief Ehlers heads for the exit7
01.10.Is Biogen Stock A Buy As It Recovers From Its Alzheimer's Flop?21
01.10.Apple, Biogen And More 'Fast Money' Picks For October 111
01.10.Biogen's Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO5
01.10.Biogen announces leadership changes2
01.10.Biogen Appoints Alfred Sandrock As EVP, Research And Development208WESTON (dpa-AFX) - Biogen (BIIB) said that it has appointed Alfred Sandrock as Executive Vice President, Research and Development, in addition to his responsibilities as Chief Medical Officer...
► Artikel lesen
01.10.After major Alzheimer's flops, Biogen's R&D chief Ehlers hits the exit4
01.10.Michael Ehlers jumps a listing ship, turning to a VC and startups as a damaged Biogen taps longtime vet Al Sandrock to take his place2
01.10.Biogen Inc.: Biogen Announces Leadership Update314Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical Operations...
► Artikel lesen
01.10.BIOGEN INC. - 8-K, Current Report2
27.09.Better Buy: Biogen vs. Amgen37
Seite:  Weiter >>
331 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
13,1,46